In the majority of cancers, this is achieved through re-expression of the enzyme telomerase, but in approximately 10%–15% of adult cancer types (and a higher proportion of paediatric solid tumours), a telomerase-independent pathway is used, termed alternative lengthening of telomeres (ALT) [1]. This evidence concerns the gene GPT and cancer.